<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1675" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1675/" /><meta name="ncbi_pagename" content="PLA2G6-Associated Neurodegeneration - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>PLA2G6-Associated Neurodegeneration - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="PLA2G6-Associated Neurodegeneration" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/03/23" /><meta name="citation_author" content="Allison Gregory" /><meta name="citation_author" content="Manju A Kurian" /><meta name="citation_author" content="Eamonn R Maher" /><meta name="citation_author" content="Penelope Hogarth" /><meta name="citation_author" content="Susan J Hayflick" /><meta name="citation_pmid" content="20301718" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1675/" /><meta name="citation_keywords" content="NBIA2" /><meta name="citation_keywords" content="PLA2G6-Related Disorders" /><meta name="citation_keywords" content="PLAN" /><meta name="citation_keywords" content="PLAN" /><meta name="citation_keywords" content="PLA2G6-Related Disorders" /><meta name="citation_keywords" content="NBIA2" /><meta name="citation_keywords" content="Atypical Neuroaxonal Dystrophy" /><meta name="citation_keywords" content="Infantile Neuroaxonal Dystrophy" /><meta name="citation_keywords" content="PLA2G6-Related Dystonia-Parkinsonism" /><meta name="citation_keywords" content="85/88 kDa calcium-independent phospholipase A2" /><meta name="citation_keywords" content="PLA2G6" /><meta name="citation_keywords" content="PLA2G6-Associated Neurodegeneration" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="PLA2G6-Associated Neurodegeneration" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Allison Gregory" /><meta name="DC.Contributor" content="Manju A Kurian" /><meta name="DC.Contributor" content="Eamonn R Maher" /><meta name="DC.Contributor" content="Penelope Hogarth" /><meta name="DC.Contributor" content="Susan J Hayflick" /><meta name="DC.Date" content="2017/03/23" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1675/" /><meta name="description" content="PLA2G6-associated neurodegeneration (PLAN) comprises a continuum of three phenotypes with overlapping clinical and radiologic features:" /><meta name="og:title" content="PLA2G6-Associated Neurodegeneration" /><meta name="og:type" content="book" /><meta name="og:description" content="PLA2G6-associated neurodegeneration (PLAN) comprises a continuum of three phenotypes with overlapping clinical and radiologic features:" /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1675/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/inad/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1675/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8A89BDE03F0261000000000A1E0376.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1675_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1675_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/pink1-pd/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/eds6/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1675_"><span class="title" itemprop="name"><i>PLA2G6</i>-Associated Neurodegeneration</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: NBIA2, <i>PLA2G6</i>-Related Disorders, PLAN</div><p class="contrib-group"><span itemprop="author">Allison Gregory</span>, MS, CGC, <span itemprop="author">Manju A Kurian</span>, MA, MRCPCH, PhD, <span itemprop="author">Eamonn R Maher</span>, MD, FRCP, FMedSci, <span itemprop="author">Penelope Hogarth</span>, MD, and <span itemprop="author">Susan J Hayflick</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1675_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1675_ai__"><div class="contrib half_rhythm"><span itemprop="author">Allison Gregory</span>, MS, CGC<div class="affiliation small">Molecular &#x00026; Medical Genetics<br />Oregon Health &#x00026; Science University<br />Portland, Oregon<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.usho@ayrogerg" class="oemail">ude.usho@ayrogerg</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Manju A Kurian</span>, MA, MRCPCH, PhD<div class="affiliation small">Molecular Neurosciences<br />Developmental Neurosciences<br />UCL-Great Ormond Street Institute of Child Health<br />London, United Kingdom<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ku.ca.lcu@nairuk.ujnam" class="oemail">ku.ca.lcu@nairuk.ujnam</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Eamonn R Maher</span>, MD, FRCP, FMedSci<div class="affiliation small">Department of Medical Genetics<br />University of Cambridge<br />Cambridge, United Kingdom<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ku.ca.mac@0001mre" class="oemail">ku.ca.mac@0001mre</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Penelope Hogarth</span>, MD<div class="affiliation small">Neurology and Molecular &#x00026; Medical Genetics<br />Oregon Health &#x00026; Science University<br />Portland, Oregon<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.usho@phtragoh" class="oemail">ude.usho@phtragoh</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Susan J Hayflick</span>, MD<div class="affiliation small">Molecular &#x00026; Medical Genetics, Pediatrics, and Neurology<br />Oregon Health &#x00026; Science University<br />Portland, Oregon<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.usho@kcilfyah" class="oemail">ude.usho@kcilfyah</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">June 19, 2008</span>; Last Update: <span itemprop="dateModified">March 23, 2017</span>.</p><p><em>Estimated reading time: 22 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="inad.Summary" itemprop="description"><h2 id="_inad_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><i>PLA2G6</i>-associated neurodegeneration (PLAN) comprises a continuum of three phenotypes with overlapping clinical and radiologic features:</p><ul><li class="half_rhythm"><div>Infantile neuroaxonal dystrophy (INAD)</div></li><li class="half_rhythm"><div>Atypical neuroaxonal dystrophy (atypical NAD)</div></li><li class="half_rhythm"><div><i>PLA2G6</i>-related dystonia-parkinsonism</div></li></ul><p>INAD usually begins between ages six months and three years with psychomotor regression or delay, hypotonia, and progressive spastic tetraparesis. Many <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children never learn to walk or lose the ability shortly after attaining it. Strabismus, nystagmus, and optic atrophy are common. Disease progression is rapid, resulting in severe spasticity, progressive cognitive decline, and visual impairment. Many affected children do not survive beyond their first decade.</p><p>Atypical NAD shows more phenotypic variability than INAD. In general, onset is in early childhood but can be as late as the end of the second decade. The presenting signs may be gait instability, ataxia, or speech delay and autistic features, which are sometimes the only evidence of disease for a year or more. Strabismus, nystagmus, and optic atrophy are common. Neuropsychiatric disturbances including impulsivity, poor attention span, hyperactivity, and emotional lability are also common. The course is fairly stable during early childhood and resembles static encephalopathy but is followed by neurologic deterioration between ages seven and 12 years.</p><p><i>PLA2G6</i>-related dystonia-parkinsonism has a variable age of onset, but most individuals present in early adulthood with gait disturbance or neuropsychiatric changes. Affected individuals consistently develop dystonia and parkinsonism (which may be accompanied by rapid cognitive decline) in their late teens to early twenties. Dystonia is most common in the hands and feet but may be more generalized. The most common features of parkinsonism in these individuals are bradykinesia, resting tremor, rigidity, and postural instability.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of <i>PLA2G6</i>-associated neurodegeneration is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>PLA2G6</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. The diagnosis of INAD or atypical NAD can be established in a proband with no identified <i>PLA2G6</i> pathogenic variants by electron microscopic examination of nerve biopsies for dystrophic axons (axonal spheroids).</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i></p><ul><li class="half_rhythm"><div>Individuals with INAD and atypical NAD. Routine pharmacologic treatment of spasticity and seizures; trial of oral or intrathecal baclofen for dystonia associated with atypical INAD; treatment by a psychiatrist for those with later-onset neuropsychiatric symptoms; fiber supplements and/or stool softener treatment for constipation; control of secretions with transdermal scopolamine patch as needed; feeding modifications as needed to prevent aspiration pneumonia and achieve adequate nutrition.</div></li><li class="half_rhythm"><div>Individuals with <i>PLA2G6</i>-related dystonia-parkinsonism. Consider treatment with dopaminergic agents; treatment of neuropsychiatric symptoms by a psychiatrist; evaluation by physical therapy for management of postural instability and gait difficulties; occupational therapy to assist with activities of daily living; feeding modifications as needed to prevent aspiration pneumonia and achieve adequate nutrition.</div></li></ul><p><i>Prevention of secondary complications:</i> Early physical therapy and orthopedic management to prevent contractures as the disease progresses; body temperature monitors may be required for individuals with progressive autonomic involvement to identify dangerous fluctuations in core body temperature.</p><p><i>Surveillance:</i> Periodic assessment of vision and hearing of nonverbal children is indicated as needed to determine the level of sensory deficits.</p></div><div><h4 class="inline">Genetic counseling.</h4><p><i>PLA2G6</i>-associated neurodegeneration is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members and prenatal testing for pregnancies at increased risk are possible if the pathogenic variants in the family are known.</p></div></div><div id="inad.GeneReview_Scope"><h2 id="_inad_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="inad.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1675/table/inad.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__inad.Tc_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_inad.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PLA2G6</i>-Associated Neurodegeneration: Included Phenotypes&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_inad.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Infantile neuroaxonal dystrophy (INAD)</div></li><li class="half_rhythm"><div>Atypical neuroaxonal dystrophy (atypical NAD)</div></li><li class="half_rhythm"><div><i>PLA2G6</i>-related dystonia-parkinsonism</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#inad.Nomenclature">Nomenclature</a>.</p></div></dd><dt>1. </dt><dd><div id="inad.TF.c.1"><p class="no_margin">For other genetic causes of these phenotypes see <a href="#inad.Differential_Diagnosis">Differential Diagnosis</a>.</p></div></dd></dl></div></div></div></div><div id="inad.Diagnosis"><h2 id="_inad_Diagnosis_">Diagnosis</h2><div id="inad.Suggestive_Findings"><h3>Suggestive Findings</h3><p><i>PLA2G6</i>-associated neurodegeneration (PLAN) comprises a continuum of three phenotypes with overlapping clinical and radiologic features:</p><ul><li class="half_rhythm"><div>Infantile neuroaxonal dystrophy (INAD)</div></li><li class="half_rhythm"><div>Atypical neuroaxonal dystrophy (atypical NAD)</div></li><li class="half_rhythm"><div><i>PLA2G6</i>-related dystonia-parkinsonism</div></li></ul><div id="inad.Infantile_Neuroaxonal_Dystrophy_INA"><h4>Infantile Neuroaxonal Dystrophy (INAD)</h4><p><i>PLA2G6</i>-associated INAD <b>should be suspected</b> in individuals with the following clinical, laboratory, radiographic, and neurophysiologic features.</p><p><b>Clinical</b></p><ul><li class="half_rhythm"><div>Onset before age three years</div></li><li class="half_rhythm"><div>Psychomotor regression (most common presenting feature)</div></li><li class="half_rhythm"><div>Early truncal hypotonia followed by spastic tetraparesis (usually with hyperreflexia in the early disease stages with progression to areflexia later in the disease course)</div></li><li class="half_rhythm"><div>Visual abnormalities: strabismus, nystagmus, optic atrophy</div></li></ul><p><b>Laboratory</b></p><ul><li class="half_rhythm"><div>Elevated aspartate aminotransferase / alanine aminotransferase ratio</div></li><li class="half_rhythm"><div>Elevated lactate dehydrogenase</div></li></ul><p><b>Radiographic</b></p><ul><li class="half_rhythm"><div>Cerebellar atrophy (see <a class="figpopup" href="/books/NBK1675/figure/inad.F1/?report=objectonly" target="object" rid-figpopup="figinadF1" rid-ob="figobinadF1">Figure 1</a>)</div></li><li class="half_rhythm"><div>T<sub>2</sub>-weighted MRI of the brain: hypointense globus pallidus (indicating iron accumulation), cortical cerebellar hyperintensities consistent with cerebellar gliosis, white matter abnormalities, thin vertically oriented corpus callosum (see <a class="figpopup" href="/books/NBK1675/figure/inad.F1/?report=objectonly" target="object" rid-figpopup="figinadF1" rid-ob="figobinadF1">Figure 1</a>), and hypertrophy of the clava [<a class="bk_pop" href="#inad.REF.illingworth.2014.183">Illingworth et al 2014</a>, <a class="bk_pop" href="#inad.REF.almaawali.2016.1035">Al-Maawali et al 2016</a>]</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col fig" id="figinadF1" co-legend-rid="figlgndinadF1"><a href="/books/NBK1675/figure/inad.F1/?report=objectonly" target="object" title="Figure 1" class="img_link icnblk_img figpopup" rid-figpopup="figinadF1" rid-ob="figobinadF1"><img class="small-thumb" src="/books/NBK1675/bin/inad-Image001.gif" src-large="/books/NBK1675/bin/inad-Image001.jpg" alt="Figure 1. A." /></a><div class="icnblk_cntnt" id="figlgndinadF1"><h4 id="inad.F1"><a href="/books/NBK1675/figure/inad.F1/?report=objectonly" target="object" rid-ob="figobinadF1">Figure 1</a></h4><p class="float-caption no_bottom_margin">A. Left axial image shows high brain iron in the globus pallidus (see arrow) on T<sub>2</sub>-weighted MRI. B. Right sagittal image shows cerebellar atrophy (see arrow).</p></div></div><p><b>Neurophysiologic</b></p><ul><li class="half_rhythm"><div>EMG (electromyogram). Evidence of denervation</div></li><li class="half_rhythm"><div>EEG (electroencephalogram). Fast rhythms</div></li><li class="half_rhythm"><div>VEP (visual evoked potential). Delayed with reduced amplitudes</div></li><li class="half_rhythm"><div>NCV (nerve conduction velocity). Distal axonal-type sensorimotor neuropathy</div></li><li class="half_rhythm"><div>Seizures that may present early or late in the disease course [<a class="bk_pop" href="#inad.REF.wu.2009.240">Wu et al 2009</a>]</div></li></ul></div><div id="inad.Atypical_Neuroaxonal_Dystrophy_NAD"><h4>Atypical Neuroaxonal Dystrophy (NAD)</h4><p><i>PLA2G6</i>-associated atypical NAD) <b>should be suspected</b> in individuals with the following clinical, radiographic, and neurophysiologic features.</p><p><b>Clinical</b></p><ul><li class="half_rhythm"><div>Onset before age 20 years</div></li><li class="half_rhythm"><div>Psychomotor regression</div></li><li class="half_rhythm"><div>Gait abnormalities</div></li><li class="half_rhythm"><div>Prominent expressive language difficulties</div></li><li class="half_rhythm"><div>Psychiatric/behavioral abnormalities including autistic-like behavior</div></li><li class="half_rhythm"><div>Visual abnormalities: nystagmus, optic atrophy</div></li><li class="half_rhythm"><div>Spasticity (without preceding hypotonia)</div></li><li class="half_rhythm"><div>Joint contractures</div></li><li class="half_rhythm"><div>Progressive dystonia and dysarthria</div></li><li class="half_rhythm"><div>Disease progression slower than in INAD</div></li></ul><p><b>Radiographic</b></p><ul><li class="half_rhythm"><div>Cerebellar atrophy</div></li><li class="half_rhythm"><div>T<sub>2</sub>-weighted MRI of the brain: hypointense globus pallidus (indicating iron accumulation)</div></li></ul><p><b>Neurophysiologic</b></p><ul><li class="half_rhythm"><div>VEP. Delayed with reduced amplitudes</div></li><li class="half_rhythm"><div>Seizures</div></li></ul></div><div id="inad.PLA2G6Related_DystoniaParkinsonism"><h4><i>PLA2G6</i>-Related Dystonia-Parkinsonism</h4><p><i>PLA2G6</i>-related dystonia-parkinsonism <b>should be suspected</b> in individuals with the following clinical and radiographic features.</p><p><b>Clinical</b></p><ul><li class="half_rhythm"><div>Onset varying from childhood to young adulthood</div></li><li class="half_rhythm"><div>Parkinsonism (tremor, bradykinesia, rigidity, and markedly impaired postural responses)</div></li><li class="half_rhythm"><div>Dystonia</div></li><li class="half_rhythm"><div>Dysarthria</div></li><li class="half_rhythm"><div>Autonomic involvement (e.g., cold/blue hands and feet, difficulty regulating core body temperature, constipation)</div></li><li class="half_rhythm"><div>Cognitive decline</div></li><li class="half_rhythm"><div>Neuropsychiatric changes</div></li><li class="half_rhythm"><div>Initial dramatic response to dopaminergic treatment followed by the early development of dyskinesias</div></li></ul><p><b>Radiographic</b></p><ul><li class="half_rhythm"><div>Cerebral atrophy</div></li><li class="half_rhythm"><div>Cerebellar atrophy</div></li><li class="half_rhythm"><div>Abnormal brain iron accumulation in the globus pallidus, substantia nigra, and/or striatum; findings are variable and may not be evident on MRI studies until late in the disease course for some individuals.</div></li><li class="half_rhythm"><div>Reduced dopamine transporter labeling similar to that seen in <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> Parkinson disease</div></li><li class="half_rhythm"><div>In some individuals, frontotemporal atrophy/hypoperfusion on single-photon emission computed tomography</div></li></ul></div></div><div id="inad.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of <i>PLA2G6</i>-associated neurodegeneration (PLAN) <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>PLA2G6</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1675/table/inad.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figinadTmoleculargenetictestingusedin" rid-ob="figobinadTmoleculargenetictestingusedin">Table 1</a>).</p><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>PLA2G6</i> is performed first and followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>PLA2G6</i> and other genes of interest (see <a href="#inad.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or genes that results in a similar clinical presentation).</div><div class="half_rhythm">For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="inad.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>PLA2G6</i>-Associated Neurodegeneration</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1675/table/inad.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__inad.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_inad.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_inad.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_inad.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_inad.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>PLA2G6</i></td><td headers="hd_h_inad.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_inad.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~85%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_inad.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_inad.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02264;12.5%&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_inad.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>7</sup></td><td headers="hd_h_inad.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_inad.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="inad.TF.1.1"><p class="no_margin">See <a href="/books/NBK1675/#inad.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="inad.TF.1.2"><p class="no_margin">See <a href="#inad.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="inad.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="inad.TF.1.4"><p class="no_margin">Of all individuals identified with <i>PLA2G6</i> pathogenic variants, approximately 10% have only one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified [NBIA International Mutation Database, unpublished data].</p></div></dd><dt>5. </dt><dd><div id="inad.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="inad.TF.1.6"><p class="no_margin">Deletion and <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> of multiple exons have been identified <a class="bk_pop" href="#inad.REF.crompton.2010.207">Crompton et al [2010]</a> (see <a href="#inad.Molecular_Genetics">Molecular Genetics</a>, <b>Pathogenic variants</b>).</p></div></dd><dt>7. </dt><dd><div id="inad.TF.1.7"><p class="no_margin">Linkage data support the presence of at least one additional INAD <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> [<a class="bk_pop" href="#inad.REF.morgan.2006.752">Morgan et al 2006</a>].</p></div></dd></dl></div></div></div><p><b>Tissue biopsy.</b> If no <i>PLA2G6</i> pathogenic variants are identified but the evolving <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> remains most consistent with INAD or atypical NAD, a biopsy for identification of dystrophic axons (axonal spheroids) can be considered. Electron microscopic (EM) examination of nerve ultrastructure should be done on one of the following preferred tissues: conjunctiva, skin, rectum, muscle, or other peripheral nerve (sural). Histopathologic evidence of dystrophic axons on biopsy from one or more of the following tissues, viewed by EM, includes:</p><ul><li class="half_rhythm"><div>Membranotubular profiles;</div></li><li class="half_rhythm"><div>Mitochondrial aggregates;</div></li><li class="half_rhythm"><div>Increased axonal diameter and thinned membrane.</div></li></ul><p>Note: (1) Because axonal spheroids accumulate with age and may not be evident in all tissues, individuals suspected to have INAD or atypical NAD without identifiable <i>PLA2G6</i> pathogenic variants may require multiple biopsies over time before axonal spheroids are identified. (2) Peripheral spheroids have not been described in pathologic specimens from persons with <i>PLA2G6</i>-associated dystonia-parkinsonism; however, limited pathologic material has been available thus far from this group.</p></div></div><div id="inad.Clinical_Characteristics"><h2 id="_inad_Clinical_Characteristics_">Clinical Characteristics</h2><div id="inad.Clinical_Description"><h3>Clinical Description</h3><p><b>Infantile neuroaxonal dystrophy</b>
<b>(INAD).</b> Onset of INAD usually occurs between ages six months and three years. The disease presents with psychomotor regression (i.e., loss of previously acquired milestones) or delay, delayed walking, or gait disturbance. A single individual with neonatal onset has been reported, with severe hypotonia and marked weakness [<a class="bk_pop" href="#inad.REF.fusco.2015.368">Fusco et al 2015</a>].</p><p>Truncal hypotonia is observed early in the disease course. Over time, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> persons develop a spastic tetraparesis, with symmetric pyramidal tract signs on clinical examination.</p><p>Visual signs and symptoms are common. Strabismus and nystagmus are early features of the disease. Later optic atrophy occurs in most individuals. Optic atrophy may be observed early as optic nerve pallor; thin optic chiasm and tracts have also been reported on brain MRI [<a class="bk_pop" href="#inad.REF.farina.1999.376">Farina et al 1999</a>].</p><p>Seizures occur in a minority of individuals as a later symptom [<a class="bk_pop" href="#inad.REF.nardocci.1999.1472">Nardocci et al 1999</a>, <a class="bk_pop" href="#inad.REF.wu.2009.240">Wu et al 2009</a>].</p><p>Autonomic involvement may present early as constipation or cold extremities. With progression, some individuals require body temperature monitors because of dangerous fluctuations in core body temperature.</p><p>The progression of disease is usually rapid. Many <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children never learn to walk or lose this ability shortly after attaining it. During the end stages of disease, severe spasticity, progressive cognitive decline, and visual impairment result in a vegetative state. Death occurs as a result of secondary illnesses such as aspiration pneumonia, associated with bulbar dysfunction. Many affected children do not survive beyond their first decade, but some survive into their teens or later. Supportive care can contribute to a longer life span by reducing the risk of infection and other complications.</p><p><b>Atypical NAD.</b> Whereas the features of INAD are relatively homogeneous, atypical disease is quite varied.</p><p>In general, onset in atypical NAD is in early childhood but can be as late as the late teens. In a series of 13 individuals, four had onset by age three years but a fairly stable course during early childhood resembling static encephalopathy, followed by neurologic deterioration between ages seven and 12 years [<a class="bk_pop" href="#inad.REF.nardocci.1999.1472">Nardocci et al 1999</a>].</p><p>The presenting signs and symptoms may be similar to INAD, including gait instability or ataxia. Others may present with speech delay and autistic features, which may remain as the only evidence of disease for a year or more, given the slow progression of atypical NAD compared to INAD [<a class="bk_pop" href="#inad.REF.gregory.2008.1402">Gregory et al 2008</a>].</p><p>Although spastic tetraparesis is evident late in the disease, it is rarely preceded by early truncal hypotonia. In contrast to classic disease, extrapyramidal findings (i.e., dystonia and dysarthria) predominate in atypical NAD. Eye findings are similar to those seen in classic INAD. Neuropsychiatric disturbances including impulsivity, poor attention span, hyperactivity, and emotional lability are also common [<a class="bk_pop" href="#inad.REF.gregory.2008.1402">Gregory et al 2008</a>].</p><p>Atypical NAD is rare, and the life span is not known; however, it is expected to be longer than that observed in classic disease.</p><p><b><i>PLA2G6</i>-related dystonia-parkinsonism.</b> To date, only a small number of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have been described [<a class="bk_pop" href="#inad.REF.karkheiran.2015.317">Karkheiran et al 2015</a>]. Age at onset has varied from four to 37 years [<a class="bk_pop" href="#inad.REF.pais_nruiz.2009.19">Pais&#x000e1;n-Ruiz et al 2009</a>, <a class="bk_pop" href="#inad.REF.pais_nruiz.2010.1791">Pais&#x000e1;n-Ruiz et al 2010</a>, <a class="bk_pop" href="#inad.REF.yoshino.2010.1356">Yoshino et al 2010</a>, <a class="bk_pop" href="#inad.REF.bower.2011.1768">Bower et al 2011</a>, <a class="bk_pop" href="#inad.REF.pais_nruiz.2012.814">Pais&#x000e1;n-Ruiz et al 2012</a>, <a class="bk_pop" href="#inad.REF.virmani.2014.245">Virmani et al 2014</a>]; however, the majority have presented in early adulthood (late teens to 20s). Of those with childhood onset, one presented with foot drag and dystonia at age ten years and the other two children presented with an unsteady gait at ages six and eight years. The youngest individual presented with stuttering speech, clumsiness, and dyslexia at age four years &#x02013; findings that may not be related to the <i>PLA2G6</i>-associated neurodegeneration (PLAN). In young adults, initial symptoms are frequently neuropsychiatric, including depression, personality changes, aggression, delusions, or paranoia. Gait disturbance is also common at presentation.</p><p>Regardless of the age at onset, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals consistently develop dystonia and parkinsonism (which may be accompanied by rapid cognitive decline) in their late teens to early twenties. Neuropsychiatric changes may precede the movement disorder or occur concomitantly. Dystonia is most common in the hands and feet but may be more generalized. The most common features of parkinsonism in these individuals are bradykinesia, resting tremor, rigidity, and postural instability. Of note, it is common to have an initially dramatic positive response to dopaminergic agents; however, this tends to be short-lived and followed quickly by the development of motor fluctuations and dyskinesias.</p><p><b>Neuropathology.</b>
<a class="bk_pop" href="#inad.REF.pais_nruiz.2012.814">Pais&#x000e1;n-Ruiz et al [2012]</a> described the neuropathologic findings in seven individuals who spanned the three forms of PLAN. Numerous axonal swellings in the basal ganglia and brain stem were observed in individuals with infantile-onset and adult-onset PLAN. They were also found in the spinal cord in the two individuals for whom cord tissue was available. Lewy bodies were widespread in both those with adult-onset and those with infantile-onset PLAN. In two <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, one with onset at 18 years and the other only specified as "childhood," the Lewy body pathology was comparable to that seen in severe, end-stage Parkinson disease. Tau pathology, to varying degrees, was also found across the PLAN spectrum.</p></div><div id="inad.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Genotype correlates with <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> to a limited extent:</p><ul><li class="half_rhythm"><div>All individuals with two <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> alleles of <i>PLA2G6</i> have INAD.</div></li><li class="half_rhythm"><div>The less severe atypical NAD <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is caused almost exclusively by pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants.</div></li><li class="half_rhythm"><div>Common pathogenic variants associated with INAD impair the catalytic activity of the PLA2G6 protein, whereas three pathogenic variants associated with <i>PLA2G6</i>-related dystonia-parkinsonism did not [<a class="bk_pop" href="#inad.REF.engel.2010.e12897">Engel et al 2010</a>].</div></li></ul></div><div id="inad.Nomenclature"><h3>Nomenclature</h3><p><b>Outdated terms</b></p><ul><li class="half_rhythm"><div><a class="bk_pop" href="#inad.REF.seitelberger.1952">Seitelberger [1952]</a> first described this condition, which was originally named Seitelberger disease.</div></li><li class="half_rhythm"><div>Karak syndrome was described in two sibs with early-onset cerebellar ataxia, dystonia, spasticity, and intellectual decline. Brain MRI findings included cerebellar atrophy and iron accumulation in the globus pallidus and substantia nigra [<a class="bk_pop" href="#inad.REF.mubaidin.2003.543">Mubaidin et al 2003</a>]. <a class="bk_pop" href="#inad.REF.morgan.2006.752">Morgan et al [2006]</a> identified pathogenic variants in <i>PLA2G6</i> in individuals with Karak syndrome, which is now included in the phenotypic spectrum of PLAN and no longer considered a clinically distinct entity; what had been described as Karak syndrome is now referred to as atypical NAD.</div></li></ul><p><b>Current nomenclature.</b> In addition to INAD, later-onset variants have been called late-infantile, juvenile, or atypical neuroaxonal dystrophy and <a href="/books/n/gene/nbia-ov/">neurodegeneration with brain iron accumulation</a> (NBIA).</p><p>The authors propose the following usage:</p><ul><li class="half_rhythm"><div><b>INAD</b> for early-onset, rapidly progressive disease</div></li><li class="half_rhythm"><div><b>Atypical NAD</b> for later childhood-onset disease with slower progression and predominant extrapyramidal findings (dystonia, dysarthria). The atypical NAD <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is expected to include a broad range of presentations including Karak syndrome.</div></li><li class="half_rhythm"><div><b><i>PLA2G6-</i>related dystonia-parkinsonism</b> for adult-onset dystonia-parkinsonism accompanied by cognitive decline and neuropsychiatric changes</div></li></ul></div><div id="inad.Prevalence"><h3>Prevalence</h3><p>Disease prevalence is not established; it is estimated at 1:1,000,000.</p></div></div><div id="inad.Genetically_Related_Allelic_Disorde"><h2 id="_inad_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p>Though still only speculative, pathogenic variants in <i>PLA2G6</i> may underlie Schindler disease as well. This may explain the discordance between the clinical and biochemical phenotypes observed in Schindler disease, which is categorized as a neuroaxonal dystrophy. Schindler disease was originally reported in sibs with early-onset, rapidly progressive psychomotor regression, evidence of axonal spheroids, and deficiency of &#x003b1;-N-acetylgalactosaminidase (&#x003b1;-NAGA) [<a class="bk_pop" href="#inad.REF.schindler.1989.1735">Schindler et al 1989</a>]. Alpha-NAGA deficiency underlies the oligosacchariduria found in Schindler disease, but its causal role in the neurologic <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> has been questioned because other persons with &#x003b1;-NAGA deficiency have a spectrum of clinical findings ranging from angiokeratoma to no abnormalities [<a class="bk_pop" href="#inad.REF.keulemans.1996.458">Keulemans et al 1996</a>, <a class="bk_pop" href="#inad.REF.bakker.2001.91">Bakker et al 2001</a>].</p><p>The authors have proposed that pathogenic variants in <i>PLA2G6</i> account for the early-onset neurodegenerative <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> that occurs in a subset of individuals with Schindler disease based on their common clinical and pathologic features, their interrelatedness, and the proximity of <i>PLA2G6</i> to <i>NAGA</i> on <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 22 [<a class="bk_pop" href="#inad.REF.westaway.2007.e64">Westaway et al 2007</a>]. Molecular genetic testing of samples from the original sibs diagnosed with Schindler disease should resolve this question; such samples have not been available.</p></div><div id="inad.Differential_Diagnosis"><h2 id="_inad_Differential_Diagnosis_">Differential Diagnosis</h2><div id="inad.Infantile_Neuroaxonal_Dystrophy_INA_1"><h3>Infantile Neuroaxonal Dystrophy (INAD)</h3><p>Early diagnosis is challenging because the initial symptoms of psychomotor regression and progression are also observed in other conditions. The observation of an elevated aspartate aminotransferase / alanine aminotransferase ratio and elevated lactate dehydrogenase in combination with these findings is more suspicious for INAD [<a class="bk_pop" href="#inad.REF.kraoua.2016.e24">Kraoua et al 2016</a>].</p><p>The degree of weakness early in the disease course may initially direct the clinician toward a myopathy or <a href="/books/n/gene/sma/">spinal muscular atrophy</a>.</p><p>Cerebellar atrophy can be detected by brain MRI before age two years in some children [<a class="bk_pop" href="#inad.REF.farina.1999.376">Farina et al 1999</a>]. The differential diagnosis for childhood cerebellar atrophy includes infantile neuronal ceroid-lipofuscinosis (CLN1 disease, Santavuori-Haltia), <a href="/books/n/gene/ataxia-telangiectas/">ataxia-telangiectasia</a>, <i>KIF1A</i>-associated hereditary spastic paraplegia (OMIM <a href="http://www.omim.org/entry/610357" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">610357</a>; see also <a href="/books/n/gene/hsp/">Hereditary Spastic Paraplegia Overview</a>), and <a href="/books/n/gene/ataxias/">hereditary ataxia</a>; however, cerebellar atrophy usually presents later in individuals with these disorders.</p><p>An estimated 40%-50% of individuals with INAD have abnormal iron accumulation in the basal ganglia (primarily the globus pallidus), which is best detected on T<sub>2</sub>-weighted MRI. For this reason, conditions included in the <a href="/books/n/gene/nbia-ov/">neurodegeneration with brain iron accumulation</a> (NBIA) category should also be considered in the differential diagnosis of INAD. Individuals with INAD have not been found to have an eye-of-the-tiger sign, which correlates very highly with <a href="/books/n/gene/pkan/">pantothenate kinase-associated neurodegeneration</a> (PKAN) [<a class="bk_pop" href="#inad.REF.hayflick.2003.33">Hayflick et al 2003</a>].</p><p>Since the identification of <i>PLA2G6</i> pathogenic variants as causative of INAD, the need for invasive nerve biopsy to aid in diagnosis has decreased. While the presence of axonal spheroids in peripheral tissues remains specific to INAD, spheroids are found in the brain in a few other conditions, including PKAN, <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> NBIA, infantile GM2 gangliosidosis (see <a href="/books/n/gene/tay-sachs/">Hexosaminidase A Deficiency</a>), <a href="/books/n/gene/npc/">Niemann-Pick disease type C</a>, and Menkes disease (see <a href="/books/n/gene/menkes/"><i>ATP7A</i>-Related Copper Transport Disorders</a>).</p></div><div id="inad.Atypical_Neuroaxonal_Dystrophy_NAD_1"><h3>Atypical Neuroaxonal Dystrophy (NAD)</h3><p>Initial speech delay and limited social interaction may be consistent with autism.</p><p>Spasticity, dystonia, and dysarthria &#x02013; findings similar to those of other forms of NBIA &#x02013; eventually predominate; high brain iron in the globus pallidus and substantia nigra has been observed in nearly all individuals, although ascertainment is likely to be biased [<a class="bk_pop" href="#inad.REF.gregory.2008.1402">Gregory et al 2008</a>]. Therefore, <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> NBIA should also be considered in the differential diagnosis of atypical NAD. <a href="/books/n/gene/pkan/">PKAN</a> may present with similar features.</p></div><div id="inad.PLA2G6Related_DystoniaParkinsonism_1"><h3><i>PLA2G6</i>-Related Dystonia-Parkinsonism</h3><p>When high brain iron is present and pathogenic variants in <i>PLA2G6</i> have not been identified, other forms of NBIA should be considered in the differential diagnosis. Atypical PKAN, Kufor-Rakeb syndrome (OMIM <a href="http://omim.org/entry/606693" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">606693</a>), MPAN (<a href="/books/n/gene/mt-mpan/">mitochondrial membrane protein-associated neurodegeneration</a>), and BPAN (<a href="/books/n/gene/bpan/">beta-propeller protein-associated neurodegeneration</a>) can present with neuropsychiatric changes, parkinsonism, and dystonia in late childhood or early adulthood. As in <i>PLA2G6</i>-related dystonia-parkinsonism, individuals with MPAN, BPAN, and Kufor-Rakeb syndrome also exhibit cognitive decline.</p><p>Other forms of early-onset dystonia-parkinsonism must also be considered, including: <a href="/books/n/gene/drd/">dopa-responsive dystonia</a>; <a href="/books/n/gene/wilson/">Wilson disease</a>; Parkinson disease 2 (<a href="/books/n/gene/jpd/">PARK2</a>); PARK6, PARK7, and PARK15 (see <a href="/books/n/gene/parkinson-overview/">Parkinson Disease Overview</a>); <a href="/books/n/gene/slc6a3-dtds/"><i>SLC6A3</i>-related dystonia-parkinsonism</a>; <a href="/books/n/gene/xdp/">X-linked dystonia-parkinsonism</a> (DYT-TAF1); <a href="/books/n/gene/rapid-odp/">DYT-ATP1A3</a>; DYT16; and <a href="/books/n/gene/spg11/">spastic paraplegia 11</a> (SPG11) [<a class="bk_pop" href="#inad.REF.schneider.2010.431">Schneider &#x00026; Bhatia 2010</a>].</p></div></div><div id="inad.Management"><h2 id="_inad_Management_">Management</h2><div id="inad.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with <i>PLA2G6</i>-associated neurodegeneration (PLAN), the following evaluations are recommended if they have not already been completed:</p><ul><li class="half_rhythm"><div>Thorough ophthalmologic examination to assess for optic atrophy</div></li><li class="half_rhythm"><div>EEG for the possibility of unrecognized seizure activity</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul><p>Note: The extent of disease is often well characterized by the time of diagnosis, since the diagnostic workup frequently includes neurophysiologic studies (EEG, EMG, nerve conduction studies, ERG [electroretinogram], and/or VEP) and brain MRI.</p></div><div id="inad.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>The following treatments for <b>infantile neuroaxonal dystrophy</b> (<b>INAD)</b> and <b>atypical NAD</b> are palliative:</p><ul><li class="half_rhythm"><div class="half_rhythm">Pharmacologic treatment of spasticity and seizures</div></li><li class="half_rhythm"><div class="half_rhythm">Trial of oral or intrathecal baclofen for those with atypical INAD who have significant dystonia (see <a href="/books/n/gene/dystonia-ov/">Dystonia Overview</a>)</div><div class="half_rhythm">Deep brain stimulation has been successfully utilized in one individual with atypical NAD who had intractable dystonia [<a class="bk_pop" href="#inad.REF.cif.2014.128">Cif et al 2014</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Treatment by a psychiatrist for those with a later-onset, more protracted course accompanied by neuropsychiatric symptoms</div></li><li class="half_rhythm"><div class="half_rhythm">Over-the-counter fiber supplements and/or stool softeners to treat constipation that is likely caused by a combination of immobility, diet, and medications</div></li><li class="half_rhythm"><div class="half_rhythm">Transdermal scopolamine patch to reduce the volume of secretions in those with excessive drooling or difficulty controlling secretions</div></li><li class="half_rhythm"><div class="half_rhythm">Measures such as a gastric feeding tube or tracheostomy as needed to prevent aspiration pneumonia</div></li></ul><p>Treatments for <b><i>PLA2G6</i>-related dystonia-parkinsonism</b> are also palliative but differ somewhat:</p><ul><li class="half_rhythm"><div>Treatment with dopaminergic agents is likely to be beneficial for the motor symptoms of parkinsonism and dystonia and may initially produce a dramatic response. In individuals treated to date, this response diminished over time, and <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals often developed prominent early dyskinesias, complicating medical management. Despite the dyskinesias, treatment with dopaminergic agents may still be indicated, as affected individuals typically experience benefit for a period of time and the dyskinesias are expected to decline after discontinuation of treatment. In one case report, an individual age 32 years with dystonia-parkinsonism developed episodes of non-painful, fixed upward gaze with neck extension that started shortly after levodopa administration and persisted until the drug wore off [<a class="bk_pop" href="#inad.REF.virmani.2014.245">Virmani et al 2014</a>]. The use of deep brain stimulation for <i>PLA2G6</i>-associated dystonia-parkinsonism has not been reported.</div></li><li class="half_rhythm"><div>Treatment by a psychiatrist for neuropsychiatric symptoms is indicated.</div></li><li class="half_rhythm"><div>Evaluation by physical therapy may guide the management of postural instability and gait difficulties.</div></li><li class="half_rhythm"><div>Occupational therapy may offer tools to assist with activities of daily living.</div></li><li class="half_rhythm"><div>Interventions such as a gastric feeding tube or tracheostomy may be needed to reduce the risk of aspiration pneumonia.</div></li></ul></div><div id="inad.Prevention_of_Secondary_Complicatio"><h3>Prevention of Secondary Complications</h3><p>A rehabilitation program including physical therapy and orthopedic management should be initiated early in the disease course to prevent contractures when the individual is permanently nonambulatory.</p><p>Body temperature monitors may be required for individuals with progressive autonomic involvement to identify dangerous fluctuations in core body temperature.</p></div><div id="inad.Surveillance"><h3>Surveillance</h3><p>Periodic assessment of vision and hearing of nonverbal children is indicated as needed to determine the level of sensory deficits.</p></div><div id="inad.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#inad.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="inad.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Women with the INAD and atypical NAD forms of PLAN have not been known to reproduce due to the relatively early onset and severity of disease.</p><p>Two women with <i>PLA2G6</i>-related dystonia-parkinsonism have been reported to reproduce [<a class="bk_pop" href="#inad.REF.pais_nruiz.2010.1791">Pais&#x000e1;n-Ruiz et al 2010</a>, <a class="bk_pop" href="#inad.REF.virmani.2014.245">Virmani et al 2014</a>]. Since onset of manifestations of PLAN has been reported as late as age 30 years, some women may become pregnant before onset of symptoms or early in the disease course. For those who may be symptomatic, the main issue is the potential for teratogenic effects of medications taken during pregnancy. It is not known whether pregnancy itself may have short- or long-term effects on the disease course for the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> pregnant woman.</p></div><div id="inad.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Because some individuals with PLAN have high brain iron and this disorder falls into the category of <a href="/books/n/gene/nbia-ov/">NBIA</a>, the option of chelation therapy is sometimes raised. The chelator deferiprone is currently under investigation for the PKAN form of NBIA. Results may inform its use in PLAN and/or lead to additional trials.</p><p>A proof-of-concept <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> strategy is currently under investigation in murine disease models of PLAN [Dr. Manju Kurian, personal communication].</p><p>Development of small molecule therapies is also under investigation in cell and murine disease models [Dr. Paul Kotzbauer, personal communication].</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for information on clinical studies for a wide range of diseases and conditions.</p></div><div id="inad.Other"><h3>Other</h3><p><b>Docosahexaenoic acid (DHA)</b> is selectively hydrolyzed from phospholipids by the action of the iPLA<sub>2</sub>-beta enzyme, the protein encoded by <i>PLA2G6.</i> Although not yet tested as an intervention in individuals with PLAN, a <i>Pla2g6</i>-mutant mouse model showed reduced DHA metabolism and signaling [<a class="bk_pop" href="#inad.REF.basselin.2010.3166">Basselin et al 2010</a>]; evidence from a more recent study showed that DHA can reverse selective iPLA<sub>2</sub>-beta inhibition [<a class="bk_pop" href="#inad.REF.mazzocchijones.2015.69">Mazzocchi-Jones 2015</a>]. Given the low risk of harm from DHA supplementation, the authors recommend its administration at a dose that is age appropriate.</p></div></div><div id="inad.Genetic_Counseling"><h2 id="_inad_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="inad.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><i>PLA2G6</i>-associated neurodegeneration (PLAN) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="inad.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual are obligate heterozygotes (i.e., carriers of one <i>PLA2G6</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Individuals with infantile neuroaxonal dystrophy (INAD) and atypical NAD have not been known to reproduce.</div></li><li class="half_rhythm"><div>All offspring of individuals with later-onset <i>PLA2G6-</i>related dystonia-parkinsonism will be obligate (unaffected) carriers.</div></li><li class="half_rhythm"><div>If the reproductive partner of a person with <i>PLA2G6-</i>related dystonia-parkinsonism is a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, the risk to their offspring of being <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> is 50% and of being <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (unaffected carriers) is 50%. The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of the homozygous offspring within the PLAN spectrum will be influenced by the type of <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> present in the carrier partner; current data are not sufficient to predict which PLAN phenotype the homozygous offspring will display.</div></li></ul><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>&#x02019;s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>PLA2G6</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="inad.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>PLA2G6</i> pathogenic variants in the family.</p></div><div id="inad.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Testing of at-risk sibs.</b> The <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> may have sibs younger or close in age who could be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>. Although early diagnosis is not likely to significantly reduce morbidity or mortality, testing of at-risk sibs may be desired:</p><ul><li class="half_rhythm"><div class="half_rhythm">If both <i>PLA2G6</i> pathogenic variants have been identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>, the sibs may be tested to determine if they have inherited both <i>PLA2G6</i> pathogenic variants.</div></li><li class="half_rhythm"><div class="half_rhythm">If the <i>PLA2G6</i> pathogenic variants have not been identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>, a plan for assessing at-risk sibs should be designed based on the primary findings in the proband and the established clinical criteria for INAD/atypical NAD/<i>PLA2G6</i>-related dystonia-parkinsonism. Evaluations are likely to include brain MRI, ophthalmologic assessment, and possibly biopsy for histologic examination of peripheral nerves (see <a href="#inad.Diagnosis">Diagnosis</a>).</div><div class="half_rhythm">Note: Neither the absence of axonal spheroids nor a normal brain MRI rules out INAD or atypical NAD, as these findings develop over time and spheroids vary by location. Diagnostic tests may need to be repeated at a later age for at-risk sibs in families without identified <i>PLA2G6</i> pathogenic variants. A normal MRI and absence of other symptoms (including regression) in a sib who is older than the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sib was when cerebellar atrophy and/or other symptoms presented is reassuring.</div></li><li class="half_rhythm"><div class="half_rhythm">Predictions of clinical course and age of onset are more challenging in asymptomatic individuals diagnosed with <i>PLA2G6</i>-related dystonia-parkinsonism than in individuals with INAD or atypical NAD. Age of onset can vary widely in individuals from the same family; additionally, some of the neuropsychiatric changes that may be present early in disease course (e.g., anxiety or depression) are also common in the general population and thus may not be attributable to the onset of <i>PLA2G6</i>-related dystonia-parkinsonism.</div></li></ul><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="inad.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once both <i>PLA2G6</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for PLAN are possible.</p></div></div><div id="inad.Resources"><h2 id="_inad_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>INADcure Foundation</b></div><div><b>Email:</b> info@INADcure.org</div><div><a href="https://inadcure.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.INADcure.org</a></div></li><li class="half_rhythm"><div><b>NBIA Disorders Association</b></div><div>2082 Monaco Court</div><div>El Cajon CA 92019-4235</div><div><b>Phone:</b> 619-588-2315</div><div><b>Fax:</b> 619-588-4093</div><div><b>Email:</b> info@NBIAdisorders.org</div><div><a href="https://www.nbiadisorders.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nbiadisorders.org</a></div></li><li class="half_rhythm"><div><b>eyeGENE - National Ophthalmic Disease Genotyping Network Registry</b></div><div><b>Phone:</b> 301-435-3032</div><div><b>Email:</b> eyeGENEinfo@nei.nih.gov</div><div><a href="https://eyegene.nih.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nei.nih.gov/eyegene</a></div></li><li class="half_rhythm"><div><b>NBIA Disorders Association Research Registry and Treat Iron-Related Childhood-Onset Neurodegeneration (TIRCON) Registry</b></div><div> CA 92019-4235</div><div><b>Phone:</b> 619-588-2315</div><div><b>Fax:</b> 619-588-4093</div><div><b>Email:</b> pwood@nbiadisorders.org</div><div><a href="http://www.nbiadisorders.org/research/patient-registry?highlight=YToxOntpOjA7czo4OiJyZWdpc3RyeSI7fQ==" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">International Patient Registry &#x00026; Biomaterial Bank</a></div></li><li class="half_rhythm"><div><b>NBIAcure</b></div><div>Center of Excellence for NBIA Clinical Care and Research</div><div>International Registry for NBIA and Related Disorders</div><div>Oregon Health &#x00026; Science University</div><div><b>Phone:</b> 503-494-4344</div><div><b>Fax:</b> 503-494-6886</div><div><b>Email:</b> gregorya@ohsu.edu</div><div><a href="http://nbiacure.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nbiacure.org</a></div></li></ul></div><div id="inad.Molecular_Genetics"><h2 id="_inad_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="inad.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>PLA2G6-Associated Neurodegeneration: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1675/table/inad.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__inad.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_inad.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_inad.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_inad.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_inad.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_inad.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_inad.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_inad.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/8398" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>PLA2G6</i></a></td><td headers="hd_b_inad.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=8398" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">22q13<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_inad.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/O60733" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">85/88 kDa calcium-independent phospholipase A2</a></td><td headers="hd_b_inad.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/PLA2G6" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PLA2G6 @ LOVD</a></td><td headers="hd_b_inad.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=PLA2G6" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PLA2G6</a></td><td headers="hd_b_inad.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=PLA2G6[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PLA2G6</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="inad.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="inad.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for PLA2G6-Associated Neurodegeneration (<a href="/omim/256600,603604,610217" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1675/table/inad.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__inad.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/256600" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">256600</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/603604" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">603604</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PHOSPHOLIPASE A2, GROUP VI; PLA2G6</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/610217" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">610217</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2B; NBIA2B</td></tr></tbody></table></div></div><div id="inad.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p><i>PLA2G6</i> encodes 85/88-kd calcium-independent phospholipase A<sub>2</sub> (iPLA<sub>2</sub>-VIA). The iPLA<sub>2</sub> family of phospholipase A<sub>2</sub> enzymes catalyzes the hydrolysis of glycerophospholipids, generating a free fatty acid (usually arachidonic acid) and a lysophospholipid. The iPLA<sub>2</sub>-VIA protein has proposed roles in phospholipid remodeling, arachidonic acid release, leukotriene and prostaglandin synthesis, and apoptosis [<a class="bk_pop" href="#inad.REF.balsinde.2005.1052">Balsinde &#x00026; Balboa 2005</a>]. The iPLA<sub>2</sub> enzymes play a critical role in cell membrane homeostasis by helping to regulate levels of phospholipids [<a class="bk_pop" href="#inad.REF.baburina.1999.9400">Baburina &#x00026; Jackowski 1999</a>]. Defects in iPLA<sub>2</sub>-VIA could lead to a relative abundance of membrane phospholipids or skewing of the proportions of specific species and secondary structural abnormalities, which may contribute to the axonal pathology observed in INAD [<a class="bk_pop" href="#inad.REF.morgan.2006.752">Morgan et al 2006</a>].</p><p><b>Gene structure.</b> The longest characterized <i>PLA2G6</i> transcript (<a href="/nuccore/NM_003560.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_003560.2</a>) has 17 exons that are alternatively spliced to create several transcript variants encoding multiple protein <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> [<a class="bk_pop" href="#inad.REF.larsson.1998.207">Larsson et al 1998</a>]. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1675/#inad.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> No commonly occurring <i>PLA2G6</i> benign variants have been identified to date.</p><p><b>Pathogenic variants.</b> The original report of pathogenic variants in <i>PLA2G6</i> described 44 unique pathogenic variants: 32 <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants, five small deletions leading to a frameshift, three <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants, two leading to amino-acid deletions without a frameshift, one <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variant, and one <a class="def" href="/books/n/gene/glossary/def-item/contiguous-gene-deletion/">contiguous gene deletion</a> [<a class="bk_pop" href="#inad.REF.morgan.2006.752">Morgan et al 2006</a>]. Multiexon deletion and <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> have been identified in several individuals [<a class="bk_pop" href="#inad.REF.crompton.2010.207">Crompton et al 2010</a>, <a class="bk_pop" href="#inad.REF.tonelli.2010.432">Tonelli et al 2010</a>, <a class="bk_pop" href="#inad.REF.yamamoto.2015.15048">Yamamoto et al 2015</a>]. Some pathogenic variants have been identified in multiple families reported to be unrelated, although several share ethnic backgrounds [NBIA International Mutation Database, unpublished data]. A <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a>, p.Val691del, has been described in a North African cohort [<a class="bk_pop" href="#inad.REF.romani.2015.178">Romani et al 2015</a>].</p><div id="inad.T.pla2g6_pathogenic_variants_discus" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p><i>PLA2G6</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1675/table/inad.T.pla2g6_pathogenic_variants_discus/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__inad.T.pla2g6_pathogenic_variants_discus_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_inad.T.pla2g6_pathogenic_variants_discus_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_inad.T.pla2g6_pathogenic_variants_discus_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_inad.T.pla2g6_pathogenic_variants_discus_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_inad.T.pla2g6_pathogenic_variants_discus_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2070_2072del</td><td headers="hd_h_inad.T.pla2g6_pathogenic_variants_discus_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val691del</td><td headers="hd_h_inad.T.pla2g6_pathogenic_variants_discus_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_003560.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_003560<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/NP_003551.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_003551<wbr style="display:inline-block"></wbr>​.2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The longest transcript (<a href="/nuccore/NM_003560.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_003560.2</a>) encodes a protein of 806 amino acids (<a href="/protein/NP_003551.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_003551.2</a>). iPLA<sub>2</sub>-VIA is one of several calcium-independent phospholipases. The protein is active as a tetramer.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The two enzymatically active <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> of the protein are predicted to be affected by all of the pathogenic variants reported to date [<a class="bk_pop" href="#inad.REF.morgan.2006.752">Morgan et al 2006</a>]. A subset of pathogenic variants would also alter the shorter enzymatically inactive isoforms, which appear to act as <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> inhibitors when incorporated in the tetramer [<a class="bk_pop" href="#inad.REF.larsson.1998.207">Larsson et al 1998</a>, <a class="bk_pop" href="#inad.REF.balsinde.2005.1052">Balsinde &#x00026; Balboa 2005</a>].</p></div></div><div id="inad.References"><h2 id="_inad_References_">References</h2><div id="inad.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="inad.REF.almaawali.2016.1035">Al-Maawali A, Yoon G, Feigenbaum AS, Halliday WC, Clarke JT, Branson HM, Banwell BL, Chitayat D, Blaser SI. Validation of the finding of hypertrophy of the clava in infantile neuroaxonal dystrophy/PLA2G6 by biometric analysis. <span><span class="ref-journal">Neuroradiology. </span>2016;<span class="ref-vol">58</span>:1035–42.</span> [<a href="/pubmed/27516098" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27516098</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.baburina.1999.9400">Baburina I, Jackowski S. Cellular responses to excess phospholipid. <span><span class="ref-journal">J Biol Chem. </span>1999;<span class="ref-vol">274</span>:9400–8.</span> [<a href="/pubmed/10092620" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10092620</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.bakker.2001.91">Bakker HD, de Sonnaville ML, Vreken P, Abeling NG, Groener JE, Keulemans JL, van Diggelen OP. Human alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency: no association with neuroaxonal dystrophy? <span><span class="ref-journal">Eur J Hum Genet. </span>2001;<span class="ref-vol">9</span>:91–6.</span> [<a href="/pubmed/11313741" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11313741</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.balsinde.2005.1052">Balsinde J, Balboa MA. Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A2 in activated cells. <span><span class="ref-journal">Cell Signal. </span>2005;<span class="ref-vol">17</span>:1052–62.</span> [<a href="/pubmed/15993747" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15993747</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.basselin.2010.3166">Basselin M, Rosa AO, Ramadan E, Cheon Y, Chang L, Chen M, Greenstein D, Wohltmann M, Turk J, Rapoport SI. Imaging decreased brain docosahexaenoic acid metabolism and signaling in iPLA2B (VIA)-deficient mice. <span><span class="ref-journal">J Lipid Res. </span>2010;<span class="ref-vol">51</span>:3166–73.</span> [<a href="/pmc/articles/PMC2952557/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2952557</span></a>] [<a href="/pubmed/20686114" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20686114</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.bower.2011.1768">Bower MA, Bushara K, Dempsey MA, Das S, Tuite PJ. Novel mutations in siblings with later-onset PLA2G6-associated neurodegeneration (PLAN). <span><span class="ref-journal">Mov Disord. </span>2011;<span class="ref-vol">26</span>:1768–69.</span> [<a href="/pubmed/21520282" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21520282</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.cif.2014.128">Cif L, Kurian MA, Gonzalez V, Garcia-Ptacek S, Roujeau T, Gelisse P, Moura de Ribeiro AM, Crespel A, Macpherson L, Coubes P. Atypical PLA2G6-associated neurodegeneration: social communication impairment, dystonia and response to deep brain stimulation. <span><span class="ref-journal">Mov Disord Clin Pract. </span>2014;<span class="ref-vol">1</span>:128–31.</span> [<a href="/pmc/articles/PMC6183017/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6183017</span></a>] [<a href="/pubmed/30363890" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30363890</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.crompton.2010.207">Crompton D, Rehal PK, MacPherson L, Foster K, Lunt P, Hughes I, Brady AF, Pike MG, De Gressi S, Morgan NV, Hardy C, Smith M, MacDonald F, Maher ER, Kurian MA. Multiplex ligation-dependent probe amplification (MLPA) analysis is an effective tool for the detection of novel intragenic PLA2G6 mutations: implications for molecular diagnosis. <span><span class="ref-journal">Mol Genet Metab. </span>2010;<span class="ref-vol">100</span>:207–12.</span> [<a href="/pubmed/20226704" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20226704</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.engel.2010.e12897">Engel LA, Jing Z, O'Brien DE, Sun M, Kotzbauer PT. Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism. <span><span class="ref-journal">PLoS One. </span>2010;<span class="ref-vol">5</span>:e12897.</span> [<a href="/pmc/articles/PMC2944820/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2944820</span></a>] [<a href="/pubmed/20886109" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20886109</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.farina.1999.376">Farina L, Nardocci N, Bruzzone MG, D'Incerti L, Zorzi G, Verga L, Morbin M, Savoiardo M. Infantile neuroaxonal dystrophy: neuroradiological studies in 11 patients. <span><span class="ref-journal">Neuroradiology. </span>1999;<span class="ref-vol">41</span>:376–80.</span> [<a href="/pubmed/10379598" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10379598</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.fusco.2015.368">Fusco C, Frattini D, Panteghini C, Pascarella R, Garavaglia B. A case of infantile neuroaxonal dystrophy of neonatal onset. <span><span class="ref-journal">J Child Neurol. </span>2015;<span class="ref-vol">30</span>:368–70.</span> [<a href="/pubmed/24870368" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24870368</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.gregory.2008.1402">Gregory A, Westaway SK, Holm IE, Kotzbauer PT, Hogarth P, Sonek S, Coryell JC, Nguyen TM, Nardocci N, Zorzi G, Rodriguez D, Desguerre I, Bertini E, Simonati A, Levinson B, Dias C, Barbot C, Carrilho I, Santos M, Malik I, Gitschier J, Hayflick SJ. Neurodegeneration associated with genetic defects in phospholipase A2. <span><span class="ref-journal">Neurology. </span>2008;<span class="ref-vol">71</span>:1402–9.</span> [<a href="/pmc/articles/PMC2676964/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2676964</span></a>] [<a href="/pubmed/18799783" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18799783</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.hayflick.2003.33">Hayflick SJ, Westaway SK, Levinson B, Zhou B, Johnson MA, Ching KH, Gitschier J. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. <span><span class="ref-journal">N Engl J Med. </span>2003;<span class="ref-vol">348</span>:33–40.</span> [<a href="/pubmed/12510040" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12510040</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.illingworth.2014.183">Illingworth MA, Meyer E, Chong WK, Manzur AY, Carr LJ, Younis R, Hardy C, McDonald F, Childs AM, Stewart B, Warren D, Kneen R, King MD, Hayflick SJ, Kurian MA. PLA2G6-associated neurodegeneration (PLAN): further expansion of the clinical, radiological and mutation spectrum associated with infantile and atypical childhood-onset disease. <span><span class="ref-journal">Mol Genet Metab. </span>2014;<span class="ref-vol">112</span>:183–9.</span> [<a href="/pmc/articles/PMC4048546/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4048546</span></a>] [<a href="/pubmed/24745848" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24745848</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.karkheiran.2015.317">Karkheiran S, Shahidi GA, Walker RH, Pais&#x000e1;n-Ruiz C. PLA2G6-associated Dystonia-Parkinsonism: Case Report and Literature Review. <span><span class="ref-journal">Tremor Other Hyperkinet Mov (N Y). </span>2015 Jul 10;<span class="ref-vol">5</span>:317.</span> [<a href="/pmc/articles/PMC4503963/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4503963</span></a>] [<a href="/pubmed/26196026" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26196026</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.keulemans.1996.458">Keulemans JL, Reuser AJ, Kroos MA, Willemsen R, Hermans MM, van den Ouweland AM, de Jong JG, Wevers RA, Renier WO, Schindler D, Coll MJ, Chabas A, Sakuraba H, Suzuki Y, van Diggelen OP. Human alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency: new mutations and the paradox between genotype and phenotype. <span><span class="ref-journal">J Med Genet. </span>1996;<span class="ref-vol">33</span>:458–64.</span> [<a href="/pmc/articles/PMC1050630/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1050630</span></a>] [<a href="/pubmed/8782044" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8782044</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.kraoua.2016.e24">Kraoua I, Romani M, Tonduti D, BenRhouma H, Zorzi G, Zibordi F, Ardissone A, Gouider-Khouja N, Ben Youssef-Turki I, Nardocci N, Valente EM. Elevated aspartate aminotransferase and lactate dehydrogenase levels are a constant finding in PLA2G6-associated neurodegeneration. <span><span class="ref-journal">Eur J Neurol. </span>2016;<span class="ref-vol">23</span>:e24–5.</span> [<a href="/pubmed/27000981" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27000981</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.larsson.1998.207">Larsson PK, Claesson HE, Kennedy BP. Multiple splice variants of the human calcium-independent phospholipase A2 and their effect on enzyme activity. <span><span class="ref-journal">J Biol Chem. </span>1998;<span class="ref-vol">273</span>:207–14.</span> [<a href="/pubmed/9417066" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9417066</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.mazzocchijones.2015.69">Mazzocchi-Jones D. Impaired corticostriatal LTP and depotentiation following iPLA2 inhibition is restored following acute application of DHA. <span><span class="ref-journal">Brain Res Bull. </span>2015;<span class="ref-vol">111</span>:69–75.</span> [<a href="/pubmed/25562715" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25562715</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.morgan.2006.752">Morgan NV, Westaway SK, Morton JE, Gregory A, Gissen P, Sonek S, Cangul H, Coryell J, Canham N, Nardocci N, Zorzi G, Pasha S, Rodriguez D, Desguerre I, Mubaidin A, Bertini E, Trembath RC, Simonati A, Schanen C, Johnson CA, Levinson B, Woods CG, Wilmot B, Kramer P, Gitschier J, Maher ER, Hayflick SJ. PLA2G6, encoding a phospholipase A(2), is mutated in neurodegenerative disorders with high brain iron. <span><span class="ref-journal">Nat Genet. </span>2006;<span class="ref-vol">38</span>:752–4.</span> [<a href="/pmc/articles/PMC2117328/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2117328</span></a>] [<a href="/pubmed/16783378" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16783378</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.mubaidin.2003.543">Mubaidin A, Roberts E, Hampshire D, Dehyyat M, Shurbaji A, Mubaidien M, Jamil A, Al-Din A, Kurdi A, Woods CG. Karak syndrome: a novel degenerative disorder of the basal ganglia and cerebellum. <span><span class="ref-journal">J Med Genet. </span>2003;<span class="ref-vol">40</span>:543–6.</span> [<a href="/pmc/articles/PMC1735513/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735513</span></a>] [<a href="/pubmed/12843330" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12843330</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.nardocci.1999.1472">Nardocci N, Zorzi G, Farina L, Binelli S, Scaioli W, Ciano C, Verga L, Angelini L, Savoiardo M, Bugiani O. Infantile neuroaxonal dystrophy: clinical spectrum and diagnostic criteria. <span><span class="ref-journal">Neurology. </span>1999;<span class="ref-vol">52</span>:1472–8.</span> [<a href="/pubmed/10227637" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10227637</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.pais_nruiz.2009.19">Pais&#x000e1;n-Ruiz C, Bhatia KP, Li A, Hernandez D, Davis M, Wood NW, Hardy J, Houlden H, Singleton A, Schneider SA. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. <span><span class="ref-journal">Ann Neurol. </span>2009;<span class="ref-vol">65</span>:19–23.</span> [<a href="/pubmed/18570303" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18570303</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.pais_nruiz.2010.1791">Pais&#x000e1;n-Ruiz C, Guevara R, Federoff M, Hanagasi H, Sina F, Elahi E, Schneider SA, Schwingenschuh P, Bajaj N, Emre M, Singleton AB, Hardy J, Bhatia KP, Brandner S, Lees AJ, Houldon H. Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBX07, and spatacsin mutations. <span><span class="ref-journal">Mov Disord. </span>2010;<span class="ref-vol">25</span>:1791–800.</span> [<a href="/pmc/articles/PMC6005705/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6005705</span></a>] [<a href="/pubmed/20669327" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20669327</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.pais_nruiz.2012.814">Pais&#x000e1;n-Ruiz C, Li A, Schneider SA, Holton JL, Johnson R, Kidd D, Chataway J, Bhatia KP, Lees AJ, Hardy J, Revesz T, Hould H. Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. <span><span class="ref-journal">Neurobiol Aging. </span>2012;<span class="ref-vol">33</span>:814–23.</span> [<a href="/pmc/articles/PMC3657696/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3657696</span></a>] [<a href="/pubmed/20619503" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20619503</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.romani.2015.178">Romani M, Kraoua I, Micalizzi A, Klaa H, Benrhouma H, Drissi C, Turki I, Castellana S, Mazza T, Valente EM, Gouider-Khouja N. Infantile and childhood onset PLA2G6-associated neurodegeneration in a large North African Cohort. <span><span class="ref-journal">Eur J Neurol. </span>2015;<span class="ref-vol">22</span>:178–86.</span> [<a href="/pubmed/25164370" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25164370</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.schindler.1989.1735">Schindler D, Bishop DF, Wolfe DE, Wang AM, Egge H, Lemieux RU, Desnick RJ. Neuroaxonal dystrophy due to lysosomal alpha-N-acetylgalactosaminidase deficiency. <span><span class="ref-journal">N Engl J Med. </span>1989;<span class="ref-vol">320</span>:1735–40.</span> [<a href="/pubmed/2733734" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2733734</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.schneider.2010.431">Schneider SA, Bhatia KP. Rare causes of dystonia parkinsonism. <span><span class="ref-journal">Curr Neurol Neurosci Rep. </span>2010;<span class="ref-vol">10</span>:431–9.</span> [<a href="/pubmed/20694531" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20694531</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.seitelberger.1952">Seitelberger F. Eine unbekannte Form von infantiler lipoid-Speicher Krankheit des Gehirns. Paper. Rome, Italy. First International Congress of Neuropathology. 1952.</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.tonelli.2010.432">Tonelli A, Romaniello R, Grasso R, Cavallini A, Righini A, Bresolin N, Borgatti R, Bassi MT. Novel splice-site mutations and a large intragenic deletion in PLA2G6 associated with a severe and rapidly progressive form of infantile neuroaxonal dystrophy. <span><span class="ref-journal">Clin Genet. </span>2010;2010;<span class="ref-vol">78</span>:432–40.</span> [<a href="/pubmed/20584031" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20584031</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.virmani.2014.245">Virmani T, Thenganatt MA, Goldman JS, Kubisch C, Greene PE, Alcalay RN. Oculogyric crises induced by levodopa in PLA2G6 parkinsonism-dystonia. <span><span class="ref-journal">Parkinsonism Relat Disord. </span>2014;<span class="ref-vol">20</span>:245–7.</span> [<a href="/pubmed/24182522" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24182522</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.westaway.2007.e64">Westaway SK, Gregory A, Hayflick SJ. Mutations in PLA2G6 and the riddle of Schindler disease. <span><span class="ref-journal">J Med Genet. </span>2007;<span class="ref-vol">44</span>:e64.</span> [<a href="/pmc/articles/PMC2597919/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2597919</span></a>] [<a href="/pubmed/17209134" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17209134</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.wu.2009.240">Wu Y, Jiang Y, Gao Z, Wang J, Yuan Y, Xiong H, Chang X, Bao X, Zhang Y, Xiao J, Wu X. Clinical study and PLA2G6 mutation screening analysis in Chinese patients with infantile neuroaxonal dystrophy. <span><span class="ref-journal">Eur J Neurol. </span>2009;<span class="ref-vol">16</span>:240–5.</span> [<a href="/pubmed/19138334" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19138334</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.yamamoto.2015.15048">Yamamoto T, Shimojima K, Shibata T, Akiyama M, Oka M, Akiyama T, Yoshinaga H, Kobayashi K. Novel PLA2G6 mutations associated with an exonic deletion due to non-allelic homologous recombination in a patient with infantile neuroaxonal dystrophy. <span><span class="ref-journal">Hum Genome Var. </span>2015 Nov 19;<span class="ref-vol">2</span>:15048.</span> [<a href="/pmc/articles/PMC4785535/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4785535</span></a>] [<a href="/pubmed/27081553" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27081553</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="inad.REF.yoshino.2010.1356">Yoshino H, Tomiyama H, Tachibana N, Ogaki K, Li Y, Funayama M, Hashimoto T, Takashima S, Hattori N. Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. <span><span class="ref-journal">Neurology. </span>2010;<span class="ref-vol">75</span>:1356–61.</span> [<a href="/pubmed/20938027" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20938027</span></a>]</div></li></ul></div></div><div id="inad.Chapter_Notes"><h2 id="_inad_Chapter_Notes_">Chapter Notes</h2><div id="inad.Acknowledgments"><h3>Acknowledgments</h3><p>This work was supported in part by grants from the National Institute of Child Health and Human Development, the National Eye Institute, L'Association Internationale de Dystrophie Neuro Axonale Infantile, and the NBIA Disorders Association. This work was made possible by support from the Oregon Clinical and Translational Research Institute (OCTRI), grant number UL1 RR024140 01 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research.</p></div><div id="inad.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>23 March 2017 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 March 2015 (ag) Revision: docosahexaenoic acid added as a treatment for PLAN</div></li><li class="half_rhythm"><div>21 August 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 April 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>1 September 2009 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> available clinically</div></li><li class="half_rhythm"><div>19 June 2008 (me) Review posted live</div></li><li class="half_rhythm"><div>14 June 2007 (ag) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1675</span><span class="label">PMID: <a href="/pubmed/20301718" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301718</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/pink1-pd/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/eds6/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1675&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1675/?report=reader">PubReader</a></li><li><a href="/books/NBK1675/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1675" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1675" style="display:none" title="Cite this Page"><div class="bk_tt">Gregory A, Kurian MA, Maher ER, et al. PLA2G6-Associated Neurodegeneration. 2008 Jun 19 [Updated 2017 Mar 23]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1675/pdf/Bookshelf_NBK1675.pdf">PDF version of this page</a> (294K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#inad.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#inad.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#inad.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#inad.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#inad.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#inad.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#inad.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#inad.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#inad.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#inad.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#inad.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#inad.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=8398[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PLA2G6</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1463034" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1463034" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1463034" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1463034" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301294" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Brashear A, Sweadner KJ, Cook JF, Swoboda KJ, Ozelius L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24575447" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Mitochondrial Membrane Protein-Associated Neurodegeneration</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Mitochondrial Membrane Protein-Associated Neurodegeneration<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gregory A, Hartig M, Prokisch H, Kmiec T, Hogarth P, Hayflick SJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28749637" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">SLC6A3</i>-Related Dopamine Transporter Deficiency Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">SLC6A3</i>-Related Dopamine Transporter Deficiency Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kurian MA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301610" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Tyrosine Hydroxylase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Tyrosine Hydroxylase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Furukawa Y, Kish S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28541650" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> SLC39A14 Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> SLC39A14 Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Tuschl K, Gregory A, Meyer E, Clayton PT, Hayflick SJ, Mills PB, Kurian MA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301718" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301718" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040c94dde089116943f338">PLA2G6-Associated Neurodegeneration - GeneReviews®</a><div class="ralinkpop offscreen_noflow">PLA2G6-Associated Neurodegeneration - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:27:48-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8A89BDE03F0261000000000A1E0376&amp;ncbi_session=CE8A89BDE040C931_2590SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1675%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1675&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1675/&amp;ncbi_pagename=PLA2G6-Associated Neurodegeneration - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8A89BDE040C931_2590SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>